Breaking News, Financial News

Allergan 3Q

Specialty pharmaceuticals sales were up 8% in the quarter to $940.6 million, while medical devices sales were down 11% to $187.2 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Allergan 3Q09 3Q Revenues: $1.1 billion (+4%) 3Q Earnings: $179.2 million (+8%) YTD Revenues: $3.3 billion (-2%) YTD Earnings: $401.1 million (-4%) Comments: Specialty pharmaceuticals sales were up 8% in the quarter to $940.6 million, while medical devices sales were down 11% to $187.2 million. Botox/Neuromodulator sales were $327.8 million (+3%). Eye Care Pharmaceuticals revenue was $535.1 million (+5%). Skin Care revenue was $62.9 million (+136%). Urologics revenue was $14.8 mil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters